ATC Group: N03AG06 Tiagabine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N03AG06 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N03 Antiepileptics
3 N03A Antiepileptics
4 N03AG Fatty acid derivatives
5 N03AG06 Tiagabine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 30 mg

Active ingredients in N03AG06

Active Ingredient Description
Tiagabine

Tiagabine is an anti-epileptic drug. Tiagabine is a potent and selective inhibitor of both neuronal and glial GABA uptake, which results in an increase in GABAergic medicated inhibition in the brain.

Related product monographs

Title Information Source Document Type  
GABITRIL Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

France (FR)

Ireland (IE)

Lithuania (LT)

Poland (PL)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.